AA
CMPX icon

ALPS Advisors’s Compass Therapeutics CMPX Stock Holding History

ALPS Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$776K Buy
146,607
+567
+0.4% +$3.27K ﹤0.01% 622
2025
Q4 		$784K Buy
146,040
+63,033
+76% +$291K ﹤0.01% 629
2025
Q3 		$291K Buy
83,007
+8,410
+11% +$26.6K ﹤0.01% 994
2025
Q2 		$194K Buy
+74,597
New +$154K ﹤0.01% 1008
2023
Q4 		– Sell
-94,115
Closed -$185K – 973
2023
Q3 		$185K Buy
94,115
+1,127
+1% +$2.79K ﹤0.01% 958
2023
Q2 		$296K Buy
+92,988
New +$292K ﹤0.01% 884

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ALPS Advisors's CMPX Position: Q1 2026 in Review

ALPS Advisors increased its Compass Therapeutics (CMPX) stake by 0.39% in Q1 2026, buying an estimated $3.27K and bringing the position to 146,607 shares worth $776K. The position accounts for ﹤0.01% of the portfolio, ranked #622.

ALPS Advisors first reported a position in CMPX in Q2 2023 and has held it in 6 quarters since. The position peaked at $784K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • ALPS Advisors held 146,607 shares of Compass Therapeutics worth $776K as of Q1 2026.
  • ALPS Advisors bought 567 Compass Therapeutics shares in Q1 2026, an estimated $3.27K.
  • Compass Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #622 holding.
  • ALPS Advisors first reported a position in Compass Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • ALPS Advisors's Compass Therapeutics position peaked at $784K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.